
French biotech company Global Bioenergies and German cars manufacturer Audi signed a new agreement focused on the implementation of residue usage, preparation of a path to commercialization and engine testing of new blends. Following the completion of a first series of engine testing and significant progresses of the isobutene bioproduction process, the two companies have agreed to start a new program.